Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  •  2019: PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.
       
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French   therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children in India.
     
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
      
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO of BMSystems, joins Bolero's Pharma/Health Advisory Board to strengthen their services and accelerate the convergence between clinical research and Real Life Data

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
      
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
      
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: www.gemma-project.eu for the World Autism Awareness Day.
     
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

BMSystems know-how and Technologies 

1-CADI™ (Computer-Augmented Deductive Intelligence)  proprietary methodologies and tools

2-CADI™ Global discovery & validation process exploiting Smart Data
(contextualized, with patients based lines, related to mechanisms data)

BMSystems Technologies (non-confidential)

  • Computer-Assisted Deductive Integration (CADI™) proprietary methodologies and tools.
  • CADI™ Search (data acquisition & mining).
  • CADI™ Architect (data organization & structuring).
  • CADI™ Fiber-N (integrative engine).
  • CADI™ View (model representation & visualization).
  • TAPE Patent: WO/2008/093010- December 2006. A technology allowing to rapidly & simultaneously introduce defined densities of random mutations in any number of selected regions within a gene while conserving intact any number of defined coding domains in this same gene (applicable to all proteins, including antibodies, enzymes, etc..).
  • AB-ACCUS patent: WO/2008/093009 - December 2006. A recombination technology allowing the rapid & efficient production of phage banks in which every individual differs from all others for any number of selected genes or other sequences.
  • RIPh patent: PCT/FR2010/050796 – May 2009. A methodology allowing to reversibly immobilize an obligate lytic phage within its bacterial host and to then extensively modify its genome without adversely affecting the phage's replicative ability.
  • CNS copatent: WO/2010/029131 - September, 2008. Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

 

 

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers